AIMCA
APLS

Alberta Investment Management Corp (AIMCo)’s Apellis Pharmaceuticals APLS Stock Holding History

Alberta Investment Management Corp (AIMCo)’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,015
Closed -$265K – 1225
2023
Q1 		$265K Buy
+4,015
New +$232K ﹤0.01% 1116

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alberta Investment Management Corp (AIMCo)'s APLS Position: Q2 2023 in Review

Alberta Investment Management Corp (AIMCo) sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 4,015 shares — an estimated $265K sold.

Alberta Investment Management Corp (AIMCo) first reported a position in APLS in Q1 2023 and held it in 1 quarter. The position peaked at $265K in Q1 2023. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Alberta Investment Management Corp (AIMCo) reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Alberta Investment Management Corp (AIMCo) sold 4,015 Apellis Pharmaceuticals shares in Q2 2023, an estimated $265K.
  • Alberta Investment Management Corp (AIMCo) first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Alberta Investment Management Corp (AIMCo)'s Apellis Pharmaceuticals position peaked at $265K in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Alberta Investment Management Corp (AIMCo)'s 13F filing for Q2 2023, filed 14 Aug 2023.